Overview
Indications
WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: Limitations of Use Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fata
Boxed Warning
FDA Black Box Warning
• 5.1 13.1 [see Warnings and Precautions (), Nonclinical Toxicology ()] In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcin
Contraindications
When this intervention should not be used
WEGOVY is contraindicated in the following conditions: • 5.1 [see Warnings and Precautions ()] A personal or family history of MTC or in patients with MEN 2. • 5.7 [see Warnings and Precautions ()] A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injecti
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
62 trials linked to this intervention
Recent Trials
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Semaglutide (substance)
- SNOMED CT
- 764283003
- UMLS CUI
- C3885068
- RxNorm CUI
- 1991302
- Labeler
- Novo Nordisk
Clinical Data
This intervention maps to 0 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.